PET Prostate Request

Patient Details

Name

Address

DOB Phone

Medicare Number ☐

Medicare Eligible PET Examinations

F-18 PSMA with whole body diagnostic CT (Head, Chest, Abdo, Pelvis) :

Plus Extremity (eg. Melanoma, Sarcoma, Myeloma, PUO, Vasculitis/Arteries, Rheumatological or where limb involvement suspected)

F-18 PMSA with localised daignostic CT (please tick region/s)

Head Neck Chest Abdo Pelvis Extremity

F-18 PMSA withnon diagnostic CT (attenuation only)

MBS ineligible items will incur an out of pocket fee. MBS items must be specialist referred.

Clinical Details

Please insert value for at least one of the following:

PSA (>10ng/ml): Gleason score (> 7):

ISUP (>2): Stage (> T2b):

Non Medicare eligible PSMA

Other Clinical Details:

Contrast Allergy
Renal Impairment
Surgery/Biopsy
Radiation Therapy
Chemotherapy
Prior Imaging
(where and when)

Initial Staging - 61563

The patient has intermediate to high-risk prostate adenocarcinoma
The patient has previously been untreated
The patient considered suitable for locoregional therapy with curative intent

Restaging - 61564

The patient has intermediate to high-risk prostate adenocarcinoma
The patient has undergone prior locoregional therapy and is considered suitable for further locoregional therapy

Referrer Details

Name

Provider Number

Signature

Address

Date

noosa radiology

IMAGING SERVICES

MRI

CT
All body regions
CT - Coronary (CTCA)
CT - Interventioal
CT - Angiography
CT - Colonography

PET & Nuclear Imaging
Prostate
Breast
Lymphoma
Melanoma
Bone Scan
Myocardial Perfusion
Lymphoscintigraphy
Thyroid Scan
Other

Ultrasound

Fluoroscopy
Barium Swallow
Other

DEXA
Bone Mineral Densitometry
Body Composition

Dental & X-ray
OPG
CT Dentascan
Cone Beam CT

SPECIALISED SERVICES

Interventional
Radiofrequency Ablation
MRI guided Biopsy & FNA
Injection

Cardiac Imaging
CT Coronary Angiography
Echocardiography
Myocardial Perfusion
Exercise Stress Test
Holter Monitoring

Sports Imaging
MRI, CT, Ultrasound
PRP
Orthokine

Obstetric Imaging
1st Trimester
Nuchal Translucency
Morphology
3D/4D Ultrasound

Breast Imaging
3D Mammography
Breast MRI
Ultrasound
Biopsy & FNA

All images available online via Noosa Radiology Connect.

Please tick if you require:

○ Film ○ CD ○ USB

To make an appointment

07 5440 9700

07 5440 9777

info@noosaradiology.com.au

0407 822 578 (sms only)

Please see overleaf for our address details.

Your referrer has recommended that you use Noosa Radiology. You may choose another provider but please discuss this with your referrer first.

www.noosaradiology.com.au

BREAST		
Staging of locally advanced (Stage III) breast Ca	61524	BREAST CANCER, Stage III, Whole body FDG PET study performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy.
Suspected metastatic or recurrent	61525	BREAST CANCER, Whole body FDG PET study performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy.
LUNG		
Solitary Pulmonary Nodule	61523	SOLITARY PULMONARY NODULE evaluation, Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
Non-Small Cell Lung Cancer - Staging	61529	NON-SMALL CELL LUNG CANCER, Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
LYMPHOMA		
HL or NHL, initial staging	61620	HL or NHL, Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, assess response to first line therapy	61622	HL or NHL, Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, restaging	61628	HL or NHL, Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
HL or NHL, assess response to second line chemo	61632	H Lor NHL, Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
HEAD & NECK		
Head and Neck Ca, staging	61598	HEAD and NECK CANCER, Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.
Suspected residual Ca	61604	HEAD and NECK CANCER, Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.
CARCINOMA		
Metastatic SCC	61610	METASTATIC sec, Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
Colorectal Carcinoma	61541	COLORECTAL CARCINOMA, Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
Oesophogeal or GEJ carcinoma	61577	OESOPHAGEAL or GEJ CARCINOMA, Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.
Ovarian carcinoma	61565	OVARIAN CARCINOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
Uterine cervix carcinoma, primary staging	61571	UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage 182 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Uterine cervix carcinoma, recurrent Ca	61575	UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
SARCOMA		
Initial staging	61640	SARCOMA, Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
Suspected residual or recurrent	61646	SARCOMA, Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
PROSTATE		
F-18 PSMA Initial staging	61563	Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. Applicable once per lifetime.
F-18 PSMA restaging	61564	Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who: a) has undergone prior locoregional therapy; and b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation Applicable twice per lifetime
BRAIN		
Alzheimer's Disease	61560	ALZHEIMER'S DISEASE, FDG PET study of the brain, performed for the diagnosis of Alzheimer's Disease, if: a) clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocat and b) the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and c) a service to which this item applies has not been performed on the patient in the previous 12 months; and d) a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer's disease. Applicable not more than 3 times per lifetime
Malignant Brain Tumour	61538	MALIGNANT BRAIN TUMOUR, FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
Refractory Epilepsy (evaluated for surgery)	61559	REFRACTORY EPILEPSY, FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
MELANOMA		
Melanoma	61553	MELANOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
OTHER		
Rare and uncommon cancer	61612	Rare and uncommon cancer , Whole body FDG PET study for the initial staging of eligible cancer types, for a patient who is considered suitable for active therapy, if: a) the eligible cancer type is: i. a rare or uncommon cancer (less than 12 cases per 100,000 persons per year); and ii. a typically FDG avid cancer, and b) there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient Applicable once per cancer diagnosis

Noosaville Medical & Professional Centre, 90 Goodchap Street, Noosaville QLD 4566

07 5440 9700

07 5440 9777

info@noosaradiology.com.au

0407 822 578

noosa radiology